Jed MD - Jazz Pharmaceuticals Senior Medicine

JAZZ Stock  USD 123.04  0.56  0.45%   

Executive

Jed MD is Senior Medicine of Jazz Pharmaceuticals PLC
Address Waterloo Exchange, Dublin, Ireland, D04 E5W7
Phone353 1 634 7800
Webhttps://www.jazzpharma.com

Jazz Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0462 % which means that it generated a profit of $0.0462 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1209 %, meaning that it created $0.1209 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.4 B in 2024, whereas Other Assets are likely to drop slightly above 136.8 M in 2024.
Jazz Pharmaceuticals PLC currently holds 5.79 B in liabilities with Debt to Equity (D/E) ratio of 2.12, implying the company greatly relies on financing operations through barrowing. Jazz Pharmaceuticals PLC has a current ratio of 3.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Jazz Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Joanne ChoiLegend Biotech Corp
N/A
Pr MDApellis Pharmaceuticals
N/A
Indrani JDAlnylam Pharmaceuticals
51
Debra DursoBumpusBlueprint Medicines Corp
54
Matthew JDProtagonist Therapeutics
53
Sheila DentonIncyte
58
Lukas MDApellis Pharmaceuticals
53
Karen Masseyargenx NV ADR
45
Anthony CascianoViridian Therapeutics
47
William MDExelixis
N/A
Gopi MBALarimar Therapeutics
53
Danielle KeatleyUltragenyx
N/A
Stina MDAscendis Pharma AS
50
Tyler NielsenDenali Therapeutics
46
Patrick MBAExelixis
48
Pamela MurphyIncyte
73
Tim RobertsLegend Biotech Corp
N/A
Doug WallaceLegend Biotech Corp
N/A
Helen MiltonViridian Therapeutics
N/A
Mark DelongApellis Pharmaceuticals
47
Scott MDProtagonist Therapeutics
N/A
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland. Jazz Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3200 people. Jazz Pharmaceuticals PLC (JAZZ) is traded on NASDAQ Exchange in USA. It is located in Waterloo Exchange, Dublin, Ireland, D04 E5W7 and employs 2,800 people. Jazz Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Jazz Pharmaceuticals PLC Leadership Team

Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Finbar Larkin, VP Operations
George Eliades, Senior Officer
Daniel Swisher, NonExecutive Employee
Patricia Carr, Senior Officer
Jed MD, Senior Medicine
Renee Gala, President COO
Andrea Flynn, VP Relations
Robert MD, Executive Development
Philip Johnson, Executive CFO
Rene Gal, President COO
John Miller, Senior Strategy
Heidi Manna, Executive Officer
Neena JD, Executive Officer
Samantha Pearce, Senior International
Bruce Cozadd, Co-Founder, Executive Chairman and CEO

Jazz Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.